Wells Fargo & Company Ocuphire Pharma, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,789 shares of OCUP stock, worth $3,653. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,789

Previous 2,966 5.97%

Holding current value

$3,653

Previous $5,000 20.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.51 - $2.23 $267 - $394	-177 Reduced 5.97%	2,789 $4,000
Q1 2024 May 10, 2024	BUY	$1.89 - $3.27 $28 - $49	15 Added 0.51%	2,966 $5,000
Q4 2023 Feb 09, 2024	BUY	$2.59 - $3.64 $23 - $32	9 Added 0.31%	2,951 $8,000
Q3 2023 Nov 13, 2023	BUY	$3.35 - $4.33 $73 - $95	22 Added 0.75%	2,942 $9,000
Q2 2023 Aug 15, 2023	BUY	$3.63 - $6.38 $21 - $38	6 Added 0.21%	2,920 $12,000
Q1 2023 May 12, 2023	BUY	$3.01 - $3.85 $6 - $7	2 Added 0.07%	2,914 $10,000
Q4 2022 Feb 13, 2023	BUY	$2.04 - $3.53 $8 - $14	4 Added 0.14%	2,912 $10,000
Q3 2022 Nov 14, 2022	BUY	$1.82 - $2.79 $7 - $11	4 Added 0.14%	2,908 $6,000
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.25 $21 - $39	12 Added 0.41%	2,904 $5,000
Q1 2022 May 16, 2022	BUY	$2.75 - $4.39 $7,672 - $12,248	2,790 Added 2735.29%	2,892 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.4 - $5.19 $119 - $181	35 Added 52.24%	102 $0
Q3 2021 Nov 15, 2021	BUY	$3.84 - $5.38 $241 - $338	63 Added 1575.0%	67 $0
Q4 2020 Feb 09, 2021	BUY	$3.76 - $8.8 $15 - $35	4 New	4 $0

Others Institutions Holding OCUP

# of Institutions

Shares Held

2.74M

Call Options Held

Put Options Held

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $27M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Ocuphire Pharma, Inc. Transaction History